CWM Advisors LLC raised its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 6.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,153 shares of the life sciences company’s stock after acquiring an additional 245 shares during the quarter. Illumina makes up approximately 0.6% of CWM Advisors LLC’s holdings, making the stock its 16th largest position. CWM Advisors LLC’s holdings in Illumina were worth $1,529,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently modified their holdings of ILMN. Jennison Associates LLC boosted its holdings in shares of Illumina by 3.7% during the 1st quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock valued at $1,764,619,000 after purchasing an additional 200,114 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Illumina by 10.1% during the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock valued at $555,173,000 after purchasing an additional 170,046 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Illumina by 0.9% during the 1st quarter. Northern Trust Corp now owns 1,660,761 shares of the life sciences company’s stock valued at $515,981,000 after purchasing an additional 14,669 shares during the last quarter. Thoroughbred Financial Services LLC boosted its holdings in shares of Illumina by 38,516.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock valued at $87,583,000 after purchasing an additional 873,560 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Illumina by 107.1% during the 1st quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock valued at $253,484,000 after purchasing an additional 421,953 shares during the last quarter. 90.95% of the stock is currently owned by hedge funds and other institutional investors.
ILMN opened at $284.77 on Friday. The stock has a market capitalization of $43.22 billion, a price-to-earnings ratio of 49.78, a PEG ratio of 2.74 and a beta of 1.10. The company has a fifty day moving average of $319.73 and a two-hundred day moving average of $315.64. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.10 and a current ratio of 6.79. Illumina, Inc. has a fifty-two week low of $268.62 and a fifty-two week high of $380.76.
In other Illumina news, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $288.36, for a total value of $951,588.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 1,220 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $309.70, for a total transaction of $377,834.00. Following the completion of the transaction, the senior vice president now owns 8,006 shares in the company, valued at $2,479,458.20. The disclosure for this sale can be found here. Insiders have sold 53,758 shares of company stock worth $17,479,206 over the last 90 days. 0.38% of the stock is currently owned by company insiders.
ILMN has been the subject of a number of analyst reports. Argus lowered their price target on shares of Illumina to $340.00 and set a “buy” rating for the company in a report on Thursday, July 18th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. UBS Group raised their target price on shares of Illumina from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Cowen reduced their target price on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating on the stock in a research report on Friday, July 12th. Finally, Bank of America lowered shares of Illumina from a “buy” rating to an “underperform” rating and set a $310.00 target price on the stock. in a research report on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $330.92.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: What are the benefits of investing in REITs?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.